Canis, Martin

[["dc.bibliographiccitation.artnumber","154272"],["dc.bibliographiccitation.journal","BioMed Research International"],["dc.contributor.author","Ihler, Friedrich"],["dc.contributor.author","Bertlich, Mattis"],["dc.contributor.author","Weiss, Bernhard G."],["dc.contributor.author","Dietzel, Steffen"],["dc.contributor.author","Canis, Martin"],["dc.date.accessioned","2018-11-07T10:03:20Z"],["dc.date.available","2018-11-07T10:03:20Z"],["dc.date.issued","2015"],["dc.description.abstract","Impairment of cochlear blood flow has been discussed as factor in the pathophysiology of various inner ear disorders. However, the microscopic study of cochlear microcirculation is limited due to small scale and anatomical constraints. Here, two-photon fluorescence microscopy is applied to visualize cochlear microvessels. Guinea pigs were injected with Fluorescein isothiocyanateor Texas red-dextrane as plasma marker. Intravital microscopy was performed in four animals and explanted cochleae from four animals were studied. The vascular architecture of the cochlea was visualized up to a depth of 90.0 +/- 22.7 mu m. Imaging yielded a mean contrast-to-noise ratio (CNR) of 3.3 +/- 1.7. Mean diameter in vivo was 16.5 +/- 6.0 mu m for arterioles and 8.0 +/- 2.4 mu m for capillaries. In explanted cochleae, the diameter of radiating arterioles and capillaries was measured with 12.2 +/- 1.6 mu m and 6.6 +/- 1.0 mu m, respectively. The difference between capillaries and arterioles was statistically significant in both experimental setups (P < 0.001 and P = 0.022, two-way ANOVA). Measured vessel diameters in vivo and ex vivo were in agreement with published data. We conclude that two-photon fluorescence microscopy allows the investigation of cochlear microvessels and is potentially a valuable tool for inner ear research."],["dc.description.sponsorship","Open Access Publikationsfonds 2015"],["dc.identifier.doi","10.1155/2015/154272"],["dc.identifier.isi","000353163300001"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/11857"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/38437"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Hindawi Publishing Corp"],["dc.relation.issn","2314-6141"],["dc.relation.issn","2314-6133"],["dc.rights","CC BY 3.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/3.0"],["dc.title","Two-Photon Microscopy Allows Imaging and Characterization of Cochlear Microvasculature In Vivo"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","European Archives of Oto-Rhino-Laryngology"],["dc.contributor.author","Spiegel, Jennifer L."],["dc.contributor.author","Jakob, Mark"],["dc.contributor.author","Kruizenga, Marie"],["dc.contributor.author","Freytag, Saskia"],["dc.contributor.author","Bertlich, Mattis"],["dc.contributor.author","Canis, Martin"],["dc.contributor.author","Ihler, Friedrich"],["dc.contributor.author","Haubner, Frank"],["dc.contributor.author","Kitz, Julia"],["dc.contributor.author","Weiss, Bernhard G."],["dc.date.accessioned","2021-04-14T08:32:11Z"],["dc.date.available","2021-04-14T08:32:11Z"],["dc.date.issued","2020"],["dc.identifier.doi","10.1007/s00405-020-06389-7"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/83839"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.relation.eissn","1434-4726"],["dc.relation.issn","0937-4477"],["dc.title","Cancer stem cell markers in adenocarcinoma of the salivary glands - reliable prognostic markers?"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","648"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Otology & Neurotology"],["dc.bibliographiccitation.lastpage","654"],["dc.bibliographiccitation.volume","38"],["dc.contributor.author","Weiss, Bernhard G."],["dc.contributor.author","Bertlich, Mattis"],["dc.contributor.author","Bettag, Stephan A."],["dc.contributor.author","Desinger, Hendrik"],["dc.contributor.author","Ihler, Friedrich"],["dc.contributor.author","Canis, Martin"],["dc.date.accessioned","2020-12-10T18:19:57Z"],["dc.date.available","2020-12-10T18:19:57Z"],["dc.date.issued","2017"],["dc.description.abstract","Objective: Disturbance of cochlear microcirculation is considered to be the final common pathway of various inner ear diseases. Hyperfibrinogenemia causing increased plasma viscosity is a known risk factor for sudden sensorineural hearing loss and may lead to a critical reduction of cochlear blood flow. The aim of this study was to evaluate the effect of a substantial reduction of plasma fibrinogen levels by drug-induced defibrinogenation for the treatment of acute hearing loss in vivo. Methods: Acute hearing loss was induced by hyperfibrinogenemia (i.v. injection of 330 mg/kg BW fibrinogen), using a guinea pig animal model. Parameters of cochlear microcirculation and hearing thresholds were quantified by intravital microscopy and evoked response audiometry. After obtaining baseline values, the course of hearing loss and disturbances of microcirculation were investigated under influence of intravenous defibrinogenation therapy (ancrod), corticosteroid, or placebo treatment, using 5 animals/group. Results: Acute hyperfibrinogenemia caused hearing loss from 10 +/- 7 to 26 +/- 10 dB SPL at baseline. Drug-induced reduction of fibrinogen levels showed a significant increase of cochlear microcirculation (1.6-fold) and recovered hearing threshold (11 +/- 6 dB SPL). Placebo or corticosteroid treatment had no effect on hearing loss (35 +/- 7 dB SPL and 32 +/- 18 dB SPL, respectively). Conclusion: Acute hyperfibrinogenemia resulted in hearing loss. Drug-induced reduction of elevated fibrinogen levels caused an increase in cochlear blood flow and a decrease in hearing thresholds. Placebo or corticosteroid treatment had no effect. Reduction of plasma fibrinogen levels could serve as a clinical treatment option for acute hearing loss."],["dc.identifier.doi","10.1097/MAO.0000000000001400"],["dc.identifier.isi","000401025800004"],["dc.identifier.issn","1531-7129"],["dc.identifier.pmid","28369007"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/75431"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","PUB_WoS_Import"],["dc.publisher","Lippincott Williams & Wilkins"],["dc.relation.issn","1537-4505"],["dc.relation.issn","1531-7129"],["dc.title","Drug-induced Defibrinogenation as New Treatment Approach of Acute Hearing Loss in an Animal Model for Inner Ear Vascular Impairment"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1631"],["dc.bibliographiccitation.issue","8"],["dc.bibliographiccitation.journal","Head & Neck"],["dc.bibliographiccitation.lastpage","1638"],["dc.bibliographiccitation.volume","39"],["dc.contributor.author","Weiss, Bernhard G."],["dc.contributor.author","Ihler, Friedrich"],["dc.contributor.author","Wolff, Hendrik A."],["dc.contributor.author","Schneider, Simon"],["dc.contributor.author","Canis, Martin"],["dc.contributor.author","Steiner, Wolfgang"],["dc.contributor.author","Welz, Christian"],["dc.date.accessioned","2020-12-10T14:06:36Z"],["dc.date.available","2020-12-10T14:06:36Z"],["dc.date.issued","2017"],["dc.identifier.doi","10.1002/hed.v39.8"],["dc.identifier.issn","1043-3074"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/69956"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Transoral laser microsurgery for treatment for hypopharyngeal cancer in 211 patients"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","859"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK"],["dc.bibliographiccitation.lastpage","866"],["dc.bibliographiccitation.volume","36"],["dc.contributor.author","Canis, Martin"],["dc.contributor.author","Martin, Alexios"],["dc.contributor.author","Ihler, Friedrich"],["dc.contributor.author","Wolff, Hendrik Andreas"],["dc.contributor.author","Kron, Martina"],["dc.contributor.author","Matthias, Christoph"],["dc.contributor.author","Steiner, Wolfgang"],["dc.date.accessioned","2018-11-07T09:39:38Z"],["dc.date.available","2018-11-07T09:39:38Z"],["dc.date.issued","2014"],["dc.description.abstract","BackgroundThe purpose of this study was to evaluate oncological and functional results of transoral laser microsurgery (TLM) in patients with T2 and T3 glottic laryngeal squamous cell carcinoma (SCC). MethodsA retrospective chart analysis was carried out. Cases were classified into categories pT2a, pT2b, and pT3. Treatment was exclusively TLMselective neck dissection and adjuvant (chemo)radiotherapy. ResultsThree hundred ninety-one patients were treated by TLM; 142 cases were category pT2a, 127 were pT2b, and 122 were pT3. Median follow-up was 71 months. Five-year overall, recurrence-free, and disease specific survival rates were 72.2%, 76.4%, and 93.2% for pT2a tumors, 64.9%, 57.3%, and 83.9% for pT2b tumors, and 58.6%, 57.8%, and 84.1% for pT3 tumors, respectively. Larynx preservation was achieved in 93% (pT2a) and 83% (pT2b and pT3). ConclusionResults are comparable to open partial or total laryngectomy and superior to primary (chemo)radiotherapy. TLM results in a lower morbidity and superior function compared to standard treatment. (c) 2013 Wiley Periodicals, Inc. Head Neck 36: 859-866, 2014"],["dc.identifier.doi","10.1002/hed.23389"],["dc.identifier.isi","000336493200019"],["dc.identifier.pmid","23720321"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/33329"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-blackwell"],["dc.relation.issn","1097-0347"],["dc.relation.issn","1043-3074"],["dc.title","Transoral laser microsurgery in treatment of pT2 and pT3 glottic laryngeal squamous cell carcinoma - results of 391 patients"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","531"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","The Laryngoscope"],["dc.bibliographiccitation.lastpage","537"],["dc.bibliographiccitation.volume","124"],["dc.contributor.author","Ihler, Friedrich"],["dc.contributor.author","Koehler, Sabrina"],["dc.contributor.author","Meyer, Alexander C."],["dc.contributor.author","Blum, Jenny"],["dc.contributor.author","Strenzke, Nicola"],["dc.contributor.author","Matthias, Christoph"],["dc.contributor.author","Canis, Martin"],["dc.date.accessioned","2018-11-07T09:44:44Z"],["dc.date.available","2018-11-07T09:44:44Z"],["dc.date.issued","2014"],["dc.description.abstract","Objectives/HypothesisTo review the results of obliteration of a preexisting mastoid cavity with abdominal fat and Vibrant Soundbridge implantation in patients with mixed hearing loss (MHL) and to compare the data with results of Vibrant Soundbridge implantation in patients with MHL without mastoid cavity and with pure sensorineural hearing loss (SNHL). Study DesignRetrospective chart analysis of 10 patients (10 ears) with MHL and preexisting mastoid cavity, 18 patients (19 ears) with MHL alone and nine patients (10 ears) with SNHL treated in one tertiary referral center. MethodsVibrant Soundbridge implantation and obliteration in case a mastoid cavity existed previously. Pure tone audiometry (average air-bone gap, average functional gain), speech audiometry (Freiburg Monosyllabic Test) and complication rate were main outcome measures. ResultsPostoperative average air-bone gap was -15.121.2 dB in patients with MHL with mastoid cavity obliteration, -7.211.4 dB in patients with MHL without mastoid cavity, and -5.7 +/- 11.2 dB in patients with SNHL. Average functional gain was 40.0 +/- 23.5 dB, 39.7 +/- 12.1 dB, and 9.5 +/- 10.6 dB. Postoperative speech discrimination rate was 77.9 +/- 20.8%, 83.3 +/- 13.6%, and 83.6 +/- 6.3%. No severe intraoperative or postoperative complications were noted. ConclusionsMastoid cavity obliteration during Vibrant Soundbridge implantation in patients with MHL and preexisting mastoid cavity is a safe procedure. The audiometric results are satisfying and comparable to those of other patient groups implanted with the same device. Level of Evidence4. Laryngoscope, 124:531-537, 2014"],["dc.description.sponsorship","MED-EL, Innsbruck, Austria"],["dc.identifier.doi","10.1002/lary.24180"],["dc.identifier.isi","000329929900041"],["dc.identifier.pmid","23918587"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/34461"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-blackwell"],["dc.relation.issn","1531-4995"],["dc.relation.issn","0023-852X"],["dc.title","Mastoid Cavity Obliteration and Vibrant Soundbridge Implantation for Patients With Mixed Hearing Loss"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","246"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","American Journal of Otolaryngology"],["dc.bibliographiccitation.lastpage","250"],["dc.bibliographiccitation.volume","35"],["dc.contributor.author","Weiss, Bernhard G."],["dc.contributor.author","Ihler, Friedrich"],["dc.contributor.author","Matthias, Christoph"],["dc.contributor.author","Canis, Martin"],["dc.date.accessioned","2018-11-07T09:43:07Z"],["dc.date.available","2018-11-07T09:43:07Z"],["dc.date.issued","2014"],["dc.description.abstract","After laryngectomy or lateral pharyngotomy for treatment of laryngeal or hypopharyngeal cancer the occurrence of a pharyngo-cutaneous fistula is a challenging complication. Especially after previous radiotherapy and expanded surgical resections of mucosa the management is demanding. Besides the prolonged hospital stay, increased treatment costs and reduced quality of life, a delayed adjuvant treatment follows the development of a fistula. Treatment strategies range from conservative procedures comprising parenteral nutrition, antibiotics and local wound care to primary surgical closure or reconstructive tissue transfer. We report three cases of using the fibrin/thrombin-coated collagen patch TachoSil (R) as a solitary or adjuvant strategy in surgical treatment. In one patient primary closure of the fistula was achieved by transoral application of the collagen patch. In the other cases a not tension free primary suture was strengthened by the adjuvant use of TachoSil (R). The healing process was rapid and straightforward in all patients. The use of TachoSil (R) may be indicated in between conservative treatment strategies and reconstructive surgery. After occurrence of a fistula the healing process is intended to be accelerated by primary closure with TachoSil (R) or by sealing of a primary suture. (C) 2014 Elsevier Inc. All rights reserved."],["dc.identifier.doi","10.1016/j.amjoto.2013.11.005"],["dc.identifier.isi","000333541800031"],["dc.identifier.pmid","24315631"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/34107"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","W B Saunders Co-elsevier Inc"],["dc.relation.issn","1532-818X"],["dc.relation.issn","0196-0709"],["dc.title","Coated collagen patches for closure of pharyngo-cutaneous fistulas"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1213"],["dc.bibliographiccitation.issue","8"],["dc.bibliographiccitation.journal","Otology & Neurotology"],["dc.bibliographiccitation.lastpage","1216"],["dc.bibliographiccitation.volume","38"],["dc.contributor.author","Bertlich, Mattis"],["dc.contributor.author","Ihler, Friedrich"],["dc.contributor.author","Weiss, Bernhard G."],["dc.contributor.author","Freytag, Saskia"],["dc.contributor.author","Jakob, Mark"],["dc.contributor.author","Strupp, Michael"],["dc.contributor.author","Pellkofer, Hannah"],["dc.contributor.author","Canis, Martin"],["dc.date.accessioned","2020-12-10T18:19:57Z"],["dc.date.available","2020-12-10T18:19:57Z"],["dc.date.issued","2017"],["dc.identifier.doi","10.1097/MAO.0000000000001510"],["dc.identifier.issn","1531-7129"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/75432"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Fingolimod (FTY-720) is Capable of Reversing Tumor Necrosis Factor Induced Decreases in Cochlear Blood Flow"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","753"],["dc.bibliographiccitation.issue","10"],["dc.bibliographiccitation.journal","International Journal of Audiology"],["dc.bibliographiccitation.lastpage","759"],["dc.bibliographiccitation.volume","53"],["dc.contributor.author","Bertlich, Mattis"],["dc.contributor.author","Ihler, Fritz"],["dc.contributor.author","Sharaf, Kariem"],["dc.contributor.author","Weiss, Bernhard G."],["dc.contributor.author","Strupp, Michael"],["dc.contributor.author","Canis, Martin"],["dc.date.accessioned","2018-11-07T09:34:52Z"],["dc.date.available","2018-11-07T09:34:52Z"],["dc.date.issued","2014"],["dc.description.abstract","Objective: Betahistine is a histamine-like drug that is used in the treatment of Meniere's disease. It is commonly believed that betahistine increases cochlear blood flow and thus decreases the endolymphatic hydrops that is the cause of Meniere's. Despite common clinical use, there is little understanding of the kinetics or effects of its metabolites. This study investigated the effect of the betahistine metabolites aminoethylpyridine, hydroxyethylpyridine, and pyridylacetic acid on cochlear microcirculation. Design: Guinea pigs were randomly assigned to one of the groups: placebo, betahistine, or equimolar amounts of aminoethylpyridine, hydroxyethylpyridine, or pyridylacetic acid. Cochlear blood flow and mean arterial pressure were recorded for three minutes before and 15 minutes after treatment. Study sample: Thirty Dunkin-Hartley guinea pigs assigned to one of five groups with six guinea pigs per group. Results: Betahistine, aminoethylpyridine, and hydroxyethylpyridine caused a significant increase in cochlear blood flow in comparison to placebo. The effect seen under aminoethylpyridin was greatest. The group treated with pyridylacetic acid showed no significant effect on cochlear blood flow. Conclusion: Aminoethylpyridine and hydroxyethylpyridine are, like betahistine, able to increase cochlear blood flow significantly. The effect of aminoethylpyridine was greatest. Pyridylacetic acid had no effect on cochlear microcirculation."],["dc.identifier.doi","10.3109/14992027.2014.917208"],["dc.identifier.isi","000341928600008"],["dc.identifier.pmid","25014609"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/32270"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Informa Healthcare"],["dc.relation.issn","1708-8186"],["dc.relation.issn","1499-2027"],["dc.title","Betahistine metabolites, Aminoethylpyridine, and Hydroxyethylpyridine increase cochlear blood flow in guinea pigs in vivo"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","3001"],["dc.bibliographiccitation.issue","8"],["dc.bibliographiccitation.journal","European Archives of Oto-Rhino-Laryngology"],["dc.bibliographiccitation.lastpage","3009"],["dc.bibliographiccitation.volume","274"],["dc.contributor.author","Weiss, Bernhard G."],["dc.contributor.author","Bertlich, Mattis"],["dc.contributor.author","Scheele, Rebecka"],["dc.contributor.author","Canis, Martin"],["dc.contributor.author","Jakob, Mark"],["dc.contributor.author","Sohns, Jan M."],["dc.contributor.author","Ihler, Friedrich"],["dc.date.accessioned","2020-12-10T14:10:29Z"],["dc.date.available","2020-12-10T14:10:29Z"],["dc.date.issued","2017"],["dc.identifier.doi","10.1007/s00405-017-4609-5"],["dc.identifier.eissn","1434-4726"],["dc.identifier.issn","0937-4477"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/70775"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Systematic radiographic evaluation of three potential implantation sites for a semi-implantable bone conduction device in 52 patients after previous mastoid surgery"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]